Ablynx is a clinical-stage biopharmaceutical company dedicated to creating new medicines which will make a real difference to patients and caregivers. More than 1,000 healthy volunteers and patients have already been treated with Nanobodies in worldwide clinical studies to date.
There are currently eight Nanobodies in clinical development. An overview of the most advanced clinical assets is provided in the table below:
More information about our clinical trial programmes can be found on Clinical trials.
This link is for reference only. Ablynx is not responsible for the content on third party websites and does not ensure the validity of the information within the websites.